ValuEngine cut shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) from a strong-buy rating to a buy rating in a report released on Friday morning.
Separately, TheStreet raised Opiant Pharmaceuticals from a c+ rating to a b rating in a research report on Monday, October 16th.
Opiant Pharmaceuticals (NASDAQ OPNT) traded down 0.03% during trading on Friday, hitting $36.58. The stock had a trading volume of 74,566 shares. The firm has a market cap of $74.51 million, a price-to-earnings ratio of 12.44 and a beta of -0.94. Opiant Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $51.90. The firm’s 50 day moving average is $35.94 and its 200 day moving average is $17.87.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its earnings results on Friday, October 13th. The technology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.70. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%. The firm had revenue of $3.77 million for the quarter. On average, analysts anticipate that Opiant Pharmaceuticals will post $0.50 earnings per share for the current year.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Opiant Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opiant Pharmaceuticals Inc. and related companies.